Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Primary Investigator
Dewaraja, Yuni
Status
OPEN TO ACCRUAL
Phase
NA
NCT Number
NCT07096999
UM Number
2024.070
Age Group
Adults
Management Group
CTSU - Oncology
Oncology Group
Genitourinary Oncology
ID (Protocol)
57480
Secondary Protocol No
HUM00257753
Scope
Unspecified
Sponsor Type
Externally Peer-Reviewed
Disease Site
Prostate
Summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Eligibility: Inclusion Criteria
  •   * * 177Lu-617 PSMA treatment scheduled for mCRPC
    •   * Clinically stable as determined by the nuclear medicine clinicians
    •   * Male
    •   * >= 18 years of age
    •   * Willing and able to provide informed consent
Exclusion Criteria
  •   * Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed